1
|
Bertozzi AI, Munzer C, Fouyssac F, Andre N, Boetto S, Leblond P, Bourdeaut F, Dufour C, Deshpande RK, Bhat KG, Mahalingam S, Muscat A, Cain J, Ferguson M, Popovski D, Algar E, Rossello FJ, Jayasekara S, Watkins DN, Hodge J, Ashley D, Hishii M, Saito M, Arai H, Han ZY, Richer W, Lucchesi C, Freneaux P, Nicolas A, Grison C, Pierron G, Delattre O, Bourdeaut F, Epari S, TS N, Gupta T, Chinnaswamy G, Sastri JG, Shetty P, Moiyadi A, Jalali R, Fay-McClymont T, Johnston D, Janzen L, Guger S, Scheinemann K, Fleming A, Fryer C, Hukin J, Mabbott D, Huang A, Bouffet E, Lafay-Cousin L, Kawamura A, Yamamoto K, Nagashima T, Bartelheim K, Benesch M, Buchner J, Gerss J, Hasselblatt M, Kortmann RD, Fleischack G, Quiroga E, Reinhard H, Schneppenheim R, Seeringer A, Siebert R, Timmermann B, Warmuth-Metz M, Schmid I, Fruhwald MC, Fruhwald MC, Bartelheim K, Seeringer A, Kerl K, Kortmann RD, Warmuth-Metz M, Hasselblatt M, Schneppenheim R, Siebert R, Klingebiel T, Al-Kofide A, Khafaga Y, Al-Hindi H, Dababo M, Ul-Haq A, Anas M, Barria MG, Siddiqui K, Hassounah M, Ayas M, Al-Shail E, Hasselblatt M, Jeibmann A, Eikmeier K, Linge A, Johann P, Koos B, Bartelheim K, Kool M, Pfister SM, Fruhwald MC, Paulus W, Hasselblatt M, Schuller U, Junckerstorff R, Rosenblum MK, Alassiri AH, Rossi S, Bartelheim K, Schmid I, Gottardo N, Toledano H, Viscardi E, Witkowski L, Nagel I, Oyen F, Foulkes WD, Paulus W, Siebert R, Schneppenheim R, Fruhwald MC, Schrey D, Malietzis G, Chi S, Dufour C, Lafay-Cousin L, Marshall L, Carceller F, Moreno L, Zacharoulis S, Bhardwaj R, Chakravadhanula M, Ozals V, Hampton C, Metpally R, Grillner P, Asmundsson J, Gustavsson B, Holm S, Johann PD, Korshunov A, Ryzhova M, Kerl K, Milde T, Witt O, Jones DTW, Hovestadt V, Gajjar A, Hasselblatt M, Fruhwald M, Pfister S, Kool M, Finetti M, Pons ADC, Selby M, Smith A, Crosier S, Wood J, Skalkoyannis B, Bailey S, Clifford S, Williamson D, Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Rutkowski S, Timmermann B, Kortmann RD, Schneppenheim R, Warmuth-Metz M, Gerss J, Siebert R, Graf N, Boos J, Nysom K, Fruhwald MC, Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M, Kool M, Bartelheim K, Schleicher S, Handgretinger R, Fruhwald M, Meisterernst M, Kerl K, Schmidt C, Ahlfeld J, Moreno N, Dittmar S, Pfister S, Fruhwald M, Kool M, Meisterernst M, Schuller U, Chan GCF, Shing MMK, Yuen HL, Li RCH, Ling SL, Slavc I, Peyrl A, Chocholous M, Azizi A, Czech T, Dieckmann K, Haberler C, Leiss U, Gotti G, Biassoni V, Schiavello E, Spreafico F, Pecori E, Gandola L, Massimino M, Mertins J, Kornelius K, Moreno N, Holsten T, Fruhwald M, Kool M, Meisterernst M, Yano H, Nakayama N, Ohe N, Ozeki M, Kanda K, Kimura T, Hori T, Fukao T, Iwama T, Weil AG, Diaz A, Gernsback J, Bhatia S, Ragheb J, Niazi T, Khatib Z, Kerl K, Holsten T, Moreno N, Zoghbi A, Meisterernst AM, Birks D, Griesinger A, Amani V, Donson A, Posner R, Dunham C, Kleinschmidt-DeMasters BK, Handler M, Vibhakar R, Foreman N, Bhardwaj R, Ozals V, Hampton C, Zhou L, Catchpoole D, Chakravadhanula M, Kakkar A, Biswas A, Suri V, Sharma M, Kale S, Mahapatra A, Sarkar C, Torchia J, Picard D, Ho KC, Khuong-Quang DA, Louterneau L, Bourgey M, Chan T, Golbourn B, Cousin LL, Taylor MD, Dirks P, Rutka JT, Bouffet E, Hawkins C, Majewski J, Kim SK, Jabado N, Huang A, Chang JHC, Confer M, Chang A, Goldman S, Dunn M, Hartsell W. ATYPICAL TERATOID RHABDOID TUMOUR. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
2
|
Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Leuschner I, Rutkowski S, Timmermann B, Kortmann RD, Koscielniak E, Schneppenheim R, Warmuth-Metz M, Gerß J, Siebert R, Graf N, Boos J, Frühwald M. Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry. Klin Padiatr 2014; 226:143-8. [DOI: 10.1055/s-0034-1368719] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- A. Seeringer
- Swabian Children’s Cancer Center, Children’s Hospital Augsburg, Germany
| | - K. Bartelheim
- Swabian Children’s Cancer Center, Children’s Hospital Augsburg, Germany
| | - K. Kerl
- Hematology and Oncology, University Children’s Hospital Münster, Germany
| | | | - I. Leuschner
- Institute of Pathology Christian-Albrechts-University Kiel, Germany
| | - S. Rutkowski
- Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B. Timmermann
- Westgerman Protontherapycenter Essen, University Essen, Germany
| | | | - E. Koscielniak
- Pediatric Hematology and Oncology, Olgahospital Stuttgart, Germany
| | - R. Schneppenheim
- Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - J. Gerß
- Institute of Biometry and Clinical Research, University of Münster, Germany
| | - R. Siebert
- Institute of Human Genetics, Christian-Albrechts-University Kiel, Germany
| | - N. Graf
- Pediatric Hematology and Oncology, University Hospital Homburg, Germany
| | - J. Boos
- Hematology and Oncology, University Children’s Hospital Münster, Germany
| | - M. Frühwald
- Swabian Children’s Cancer Center, Children’s Hospital Augsburg, Germany
| |
Collapse
|
3
|
Benesch M, Bartelheim K, Fleischhack G, Gruhn B, Schlegel PG, Witt O, Stachel KD, Hauch H, Urban C, Quehenberger F, Massimino M, Pietsch T, Hasselblatt M, Giangaspero F, Kordes U, Schneppenheim R, Hauser P, Klingebiel T, Frühwald MC. High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplant 2014; 49:370-5. [PMID: 24419520 DOI: 10.1038/bmt.2013.208] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 11/12/2013] [Accepted: 11/12/2013] [Indexed: 12/19/2022]
Abstract
A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. Nine patients presented with metastatic disease at diagnosis. A partial or subtotal resection was achieved in 11, a total resection in five and a biopsy in three patients. Patients received a median of six chemotherapy cycles prior to HDCT. Additional radiotherapy was performed in 14 patients (first-line, n=9; following progression, n=5). Six patients underwent tandem auto-SCT. Disease status before HDCT was CR in six, PR in eight, stable disease in two and progressive disease (PD) in two patients (data missing, n=1). With a median follow-up of 16 months, 14 patients progressed. Estimated progression-free and OS at 2 years were 29% (±11%) and 50% (±12%), respectively. At last follow-up, eight patients were alive (first CR, n=4; second CR, n=2; PR, n=1; PD, n=1). Eleven patients died of PD. Median time-to-progression was 14 months. Selected patients with AT/RT might benefit from HDCT with radiotherapy. The definitive impact of this treatment modality has to be evaluated prospectively in a randomized trial.
Collapse
Affiliation(s)
- M Benesch
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - K Bartelheim
- Swabian Children's Cancer Center, Children's Hospital Augsburg, Augsburg, Germany
| | - G Fleischhack
- Pediatrics III, University Hospital of Essen, Essen, Germany
| | - B Gruhn
- Department of Pediatrics, Jena University Hospital, Jena, Germany
| | - P G Schlegel
- Department of Pediatric Hematology, Oncology and Neurooncology, University Children's Hospital Würzburg, Würzburg, Germany
| | - O Witt
- Department of Pediatric Oncology, Hematology, Immunology and Pneumonology, Children's Hospital, University of Heidelberg, Heidelberg, Germany
| | - K D Stachel
- Children's University Hospital, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
| | - H Hauch
- Department of Pediatric Hematology and Oncology, Justus Liebig University Gießen, Gießen, Germany
| | - C Urban
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria
| | - F Quehenberger
- Institute for Medical Statistics, Medical University of Graz, Graz, Austria
| | - M Massimino
- Department of Pediatrics, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
| | - T Pietsch
- Institute of Neuropathology, University of Bonn, Bonn, Germany
| | - M Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Münster, Germany
| | - F Giangaspero
- 1] Department of Radiological, Oncological and Anatomo-pathological Sciences, University La Sapienza, Rome, Italy [2] IRCCS Neuromed, Pozzilli, Italy
| | - U Kordes
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - R Schneppenheim
- Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Hauser
- Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - T Klingebiel
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, J. W. Goethe University Children's Hospital of Frankfurt, Frankfurt, Germany
| | - M C Frühwald
- 1] Swabian Children's Cancer Center, Children's Hospital Augsburg, Augsburg, Germany [2] Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany
| |
Collapse
|
4
|
Krueger CM, Berdov BA, Roman LA, Luft AV, Lampe P, Lindhofer H, Bartelheim K, Klein A, Heiss MM. Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15529] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Stroehlein MA, Gruetzner KU, Tarabichi A, Jauch KW, Bartelheim K, Lindhofer H, Von Roemeling R, Heiss MM. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2544] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2544 Background: Peritoneal carcinomatosis (PC) due to GI-tract cancer is an advanced tumor stage with poor survival. At present, no standard therapy has been recommended, as chemotherapy and surgery showed only limited efficacy in affected patients. When applied intraperitoneally (i.p.), the trifunctional antibody catumaxomab could be shown to destroy intraperitoneal tumor cells in patients with malignant ascites due to ovarian cancer. While binding simultaneously to EpCAM (on tumor cells), CD3 (T cells) and, via the Fc region, to Fc gamma receptor 1 and 3 on accessory cells, it induces a complex immunoreaction against epithelial tumor cells. The aim of this study was to investigate clinical efficacy of i.p. catumaxomab therapy in patients with PC compared to a matched control group. Methods: Between 2003 and 2005, 22 patients with PC due to cancer of colon (n=10), stomach (8), pancreas (3) and CUP (1) received treatment with catumaxomab within a phase I study. Treatment consisted of 3 to 4 i.p. applications (10–200 μg) of escalating catumaxomab doses. The survival was compared with patients receiving conventional therapies in a matched-pair analysis regarding sex, age, tumor surgery, chemotherapy, and extent of PC. Patients with existing ileus and clinically significant ascites were not included. Results: Follow up of patients receiving catumaxomab showed a median survival of 12.2 months (range 2–34) after first diagnosis of peritoneal carcinomatosis vs. 9.7 months (range 1–40) in patients with conventional treatment (p=0.005; log-rank). These data will be updated at presentation. Conclusion: Intraperitoneal treatment with the trifunctional antibody catumaxomab may be an attractive option for treatment of patients with peritoneal carcinomatosis due to GI-tract cancer. The convincing results have to be further investigated in clinical phase II/III trials. [Table: see text]
Collapse
Affiliation(s)
- M. A. Stroehlein
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - K. U. Gruetzner
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - A. Tarabichi
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - K. W. Jauch
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - K. Bartelheim
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - H. Lindhofer
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - R. Von Roemeling
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| | - M. M. Heiss
- Hospital Cologne-Merheim, Cologne, Germany; University Hospital Groβhadern, Munich, Germany; Fresenius Biotech, Munich, Germany; Trion Pharma, Munich, Germany
| |
Collapse
|
6
|
Stroehlein MA, Lordick F, Ruettinger D, Gruetzner U, Menzel H, Bartelheim K, Jaeger M, Lindhofer H, Jauch KW, Peschel C, Heiss MM. Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2529] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Stroehlein
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - F. Lordick
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - D. Ruettinger
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - U. Gruetzner
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - H. Menzel
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - K. Bartelheim
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - M. Jaeger
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - H. Lindhofer
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - K.-W. Jauch
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - C. Peschel
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| | - M. M. Heiss
- Univ of Witten-Herdecke, Cologne, Germany; Tech Univ of Munich, Munich, Germany; Univ of Munich, Munich, Germany; Fresenius Biotech, Munich, Germany; TRION Pharma, Munich, Germany
| |
Collapse
|
7
|
Ridwelski K, Kettner E, Fahlke J, Bartelheim K, Hitzl M, Schulze B, Koeber R, Michaelis U, Naujoks K, Clemens MR. Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Ridwelski
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - E. Kettner
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - J. Fahlke
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - K. Bartelheim
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - M. Hitzl
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - B. Schulze
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - R. Koeber
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - U. Michaelis
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - K. Naujoks
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - M. R. Clemens
- Städtisches Klinikum, Magdeburg, Germany; Universitätsklinikum, Magdeburg, Germany; Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| |
Collapse
|
8
|
Bartelheim K, Ognerubov NA, Semiglazov VF, Vtoraya OM, Kaletta C, Reichenberger I, Michaelis U, Naujoks K, Clemens M. Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Bartelheim
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - N. A. Ognerubov
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - V. F. Semiglazov
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - O. M. Vtoraya
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - C. Kaletta
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - I. Reichenberger
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - U. Michaelis
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - K. Naujoks
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| | - M. Clemens
- Munich Biotech AG, Neuried, Germany; Krankenanstalt Mutterhaus Trier, Trier, Germany
| |
Collapse
|